Head to Head Review: Synergy CHC Corp. (Uplisting) (NASDAQ:SNYR) & Mind Medicine (MindMed) (NASDAQ:MNMD)

Synergy CHC Corp. (Uplisting) (NASDAQ:SNYR) and Mind Medicine (MindMed) (NASDAQ:MNMD) are both small-cap consumer staples companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Profitability

This table compares Synergy CHC Corp. (Uplisting) and Mind Medicine (MindMed)’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Synergy CHC Corp. (Uplisting)	N/A	N/A	N/A
Mind Medicine (MindMed)	N/A	-47.56%	-35.55%

Institutional & Insider Ownership

27.9% of Mind Medicine (MindMed) shares are owned by institutional investors. 2.3% of Mind Medicine (MindMed) shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Synergy CHC Corp. (Uplisting) and Mind Medicine (MindMed)”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synergy CHC Corp. (Uplisting)	$26.01 million	1.21	N/A	N/A	N/A
Mind Medicine (MindMed)	N/A	N/A	-$95.73 million	($2.26)	-3.02

Synergy CHC Corp. (Uplisting) has higher revenue and earnings than Mind Medicine (MindMed).

Analyst Ratings

This is a summary of current recommendations for Synergy CHC Corp. (Uplisting) and Mind Medicine (MindMed), as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synergy CHC Corp. (Uplisting)	0	0	1	1	3.50
Mind Medicine (MindMed)	0	0	10	3	3.23

Synergy CHC Corp. (Uplisting) currently has a consensus target price of $10.00, suggesting a potential upside of 175.48%. Mind Medicine (MindMed) has a consensus target price of $25.11, suggesting a potential upside of 267.66%. Given Mind Medicine (MindMed)’s higher possible upside, analysts clearly believe Mind Medicine (MindMed) is more favorable than Synergy CHC Corp. (Uplisting).

Summary

Mind Medicine (MindMed) beats Synergy CHC Corp. (Uplisting) on 5 of the 9 factors compared between the two stocks.

About Synergy CHC Corp. (Uplisting)

Synergy CHC Corp. engages in the marketing and distribution of branded health and wellness products. The company was founded on December 29, 2010 and is headquartered in Westbrook, ME.

About Mind Medicine (MindMed)

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.